Brokers Issue Forecasts for STOK FY2025 Earnings

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Chardan Capital issued their FY2025 earnings per share estimates for shares of Stoke Therapeutics in a research report issued on Monday, March 24th. Chardan Capital analyst R. Li forecasts that the company will post earnings per share of ($1.75) for the year. Chardan Capital currently has a “Buy” rating and a $24.00 target price on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.01) per share.

Several other brokerages have also issued reports on STOK. HC Wainwright reissued a “buy” rating and set a $47.00 target price on shares of Stoke Therapeutics in a research note on Wednesday, March 19th. Needham & Company LLC reiterated a “buy” rating and set a $22.00 price objective on shares of Stoke Therapeutics in a report on Tuesday, March 18th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Stoke Therapeutics in a research note on Tuesday, December 10th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $24.67.

Stoke Therapeutics Stock Down 4.4 %

Shares of STOK stock opened at $7.40 on Thursday. The firm has a 50 day moving average of $9.40 and a 200-day moving average of $11.27. The company has a market cap of $400.18 million, a price-to-earnings ratio of -3.52 and a beta of 0.99. Stoke Therapeutics has a 52 week low of $7.18 and a 52 week high of $17.58.

Stoke Therapeutics (NASDAQ:STOK) last released its earnings results on Monday, March 24th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.38. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The business had revenue of $22.61 million during the quarter, compared to analysts’ expectations of $4.20 million.

Insider Buying and Selling at Stoke Therapeutics

In other news, insider Barry Ticho sold 3,884 shares of the stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $33,674.28. Following the completion of the sale, the insider now directly owns 63,962 shares of the company’s stock, valued at $554,550.54. This represents a 5.72 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Edward M. Md Kaye sold 10,382 shares of the firm’s stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $90,011.94. Following the completion of the transaction, the director now owns 148,253 shares in the company, valued at $1,285,353.51. This represents a 6.54 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 16,532 shares of company stock valued at $143,332. Corporate insiders own 11.30% of the company’s stock.

Hedge Funds Weigh In On Stoke Therapeutics

A number of hedge funds have recently bought and sold shares of the company. RTW Investments LP raised its holdings in shares of Stoke Therapeutics by 10.1% in the fourth quarter. RTW Investments LP now owns 5,123,525 shares of the company’s stock valued at $56,512,000 after purchasing an additional 471,240 shares during the last quarter. Baker BROS. Advisors LP boosted its holdings in Stoke Therapeutics by 6.1% during the fourth quarter. Baker BROS. Advisors LP now owns 4,633,838 shares of the company’s stock worth $51,111,000 after purchasing an additional 265,395 shares during the last quarter. Toronto Dominion Bank bought a new stake in Stoke Therapeutics in the 4th quarter worth about $35,001,000. State Street Corp grew its position in Stoke Therapeutics by 8.6% in the 3rd quarter. State Street Corp now owns 1,728,888 shares of the company’s stock worth $21,248,000 after purchasing an additional 137,145 shares in the last quarter. Finally, Assenagon Asset Management S.A. increased its stake in Stoke Therapeutics by 2.9% in the 4th quarter. Assenagon Asset Management S.A. now owns 1,350,925 shares of the company’s stock valued at $14,901,000 after buying an additional 38,446 shares during the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.